{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(23)"],"submitter":["Bou S"],"pubmed_abstract":["We report here the long-term results of marker-less respiratory-gated proton therapy (PT), without fiducial markers for hepatocellular carcinoma (HCC), which was planned using a four-dimensional computed tomography technique. Local tumor control (LTC) and overall survival (OS) were estimated using the Kaplan-Meier method. Toxicity was graded per CTCAE v5.0. Patients (n = 105; median age 73 years, range 38-90 years) with 128 lesions were treated. The median radiation dose was 66 gray relative biological effectiveness (GyRBE) (range, 52.8-82.5 GyRBE) delivered in 2.0 to 6.6 GyRBE fractions, depending on lesion volume, the involved liver, and the patient's condition. The median follow-up of surviving patients was 63 months (range, 1-126 months), and the 5-year LTC and OS rates were 93.2% and "],"journal":["Cancers"],"pagination":["5842"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9735597"],"repository":["biostudies-literature"],"pubmed_title":["Long-Term Results of Proton Therapy for Hepatocellular Carcinoma Using Four-Dimensional Computed Tomography Planning without Fiducial Markers."],"pmcid":["PMC9735597"],"pubmed_authors":["Matsumoto S","Yamamoto K","Aoyagi H","Takamatsu S","Kondou T","Maeda Y","Sasaki M","Kawamura M","Kobayashi S","Tatebe H","Tamamura H","Bou S","Sato Y","Gabata T","Shibata S","Tameshige Y","Asahi S","Sunagozaka H"],"additional_accession":[]},"is_claimable":false,"name":"Long-Term Results of Proton Therapy for Hepatocellular Carcinoma Using Four-Dimensional Computed Tomography Planning without Fiducial Markers.","description":"We report here the long-term results of marker-less respiratory-gated proton therapy (PT), without fiducial markers for hepatocellular carcinoma (HCC), which was planned using a four-dimensional computed tomography technique. Local tumor control (LTC) and overall survival (OS) were estimated using the Kaplan-Meier method. Toxicity was graded per CTCAE v5.0. Patients (n = 105; median age 73 years, range 38-90 years) with 128 lesions were treated. The median radiation dose was 66 gray relative biological effectiveness (GyRBE) (range, 52.8-82.5 GyRBE) delivered in 2.0 to 6.6 GyRBE fractions, depending on lesion volume, the involved liver, and the patient's condition. The median follow-up of surviving patients was 63 months (range, 1-126 months), and the 5-year LTC and OS rates were 93.2% and ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-05T10:33:32.039Z","creation":"2025-04-05T10:33:32.039Z"},"accession":"S-EPMC9735597","cross_references":{"pubmed":["36497323"],"doi":["10.3390/cancers14235842"]}}